PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...

This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...

(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of ...

In November 2023, the United States Food and Drug Administration (FDA) approved enzalutamide, with or without concurrent leuprolide therapy, for non-metastatic hormone-sensitive prostate cancer (M0 ...

(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Daniel George discussing real-world treatment and clinical outcomes in patients with ...

(UroToday.com) The 2024 SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Eric Jonasch discussing a phase 1B/2 study of combination 177 Lu Girentuximab + ...

(UroToday.com) The 2024 SUO annual meeting included a health services session, featuring a presentation by Dr. Ann Raldow discussing novel approaches to radiotherapy to reduce patient burden. Frequent ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Prostate Cancer Session I. Dr. Okyaz Eminaga ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3 rd – 6 th, 2024 was host to a prostate cancer session. Dr. Soroush Rais-Bahrami ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3 rd – 6 th, 2024 was host to a prostate cancer poster session. Dr. A. Oliver Sartor ...